We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News : Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les...
Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les...
The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down...
Regulatory News: Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les...
A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing...
L’objectif principal de cette étude de phase 2B était de démontrer que AEF0117 réduit la consommation de cannabis et de déterminer les critères d’évaluation et les doses optimales à utiliser...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.09 | 54.7738693467 | 1.99 | 3.56 | 1.9 | 2082 | 1.90798399 | DE |
4 | 1.08 | 54 | 2 | 3.56 | 1.9 | 1360 | 1.99464978 | DE |
12 | -0.4 | -11.4942528736 | 3.48 | 3.68 | 1.9 | 1619 | 2.44175663 | DE |
26 | -8.72 | -73.8983050847 | 11.8 | 12 | 1.9 | 1028 | 3.39426356 | DE |
52 | -10.42 | -77.1851851852 | 13.5 | 13.6 | 1.9 | 679 | 5.81579047 | DE |
156 | -10.42 | -77.1851851852 | 13.5 | 14.48 | 1.9 | 685 | 10.4669312 | DE |
260 | -10.42 | -77.1851851852 | 13.5 | 14.48 | 1.9 | 685 | 10.4669312 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions